Under this program, Center for Translational Research (CTR), a part of CHI’s Institute for Research and Innovation, will provide fresh human tumor samples for CDAS to perform biomarker and standard-of-care drug resistance/sensitivity studies on the samples.
CDAS will grow the CTR samples under various experimental conditions, including traditional two-dimensional cell culture, three-dimensional (3-D) in vitro culture, and in vivo culture in mice, and the CTR will supply key treatment history and diagnostic data for these tumor sources.
CDAS provides oncology drug discovery assays based on a variety of biological output parameters such as proliferation, viability, apoptosis or specific biomarkers applied under conventional monolayer cell culture conditions.
This new collaboration allows these testing methods to be extended to fresh tumor cells maintained under potentially more natural and disease-relevant conditions.
Caliper Life Sciences president and CEO Kevin Hrusovsky said their personalized medicine strategies facilitate the development of therapeutics and companion diagnostics to ultimately improve treatment success rates.